Piper Jaffray analyst Joseph Catanzaro reiterates an Overweight rating on Aerie Pharmaceuticals after hosting investor meetings with management and conducting a key opinion leader survey. Management, investor and physician feedback all point to expectations for continued growth in the company's glaucoma franchise, Catanzaro tells investors in a research note. Doctor feedback supports expected increased use of Rhopressa and Rocklatan in the next six months and indicates the main issue limiting their prescribing is managed care, which appears to be improving and should continue to improve, Catanzaro says. He did, however, lower his Q3 revenue estimate for Aerie to $18M from $20M to reflect Q3 script data.